C
앱클론
174900KOSDAQ의료용품 및 기타 의약 관련제품 제조업50.0 / 100
Reference Date: 2026-04-13
Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 43.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Appclone is a biotech company specializing in the development of monoclonal antibody-based pharmaceuticals. It focuses on creating 'Biosynergy' drugs that enhance efficacy when combined with existing medications and 'Biounique' antibodies with distinct mechanisms of action for monotherapy. The company also leverages its 'Affibody' technology and human antibody library to develop innovative treatment solutions.
Number of Employees
66people
Average Salary
57.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 19.894.0Point
PBR
16.58Industry Average 1.620.0Point
10.2x industry avg (risky)
ROE
-39.86Industry Average -4.893.5Point
8.2x industry avg (excellent)
Debt Ratio
1.58Industry Average 8.888.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲41.4% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼23.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -45.9% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (51%)
Current 50,300Won52-week high 89,10052-week low 8,960
1-month return0.0Point
1m -43.55% (strong drop)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
6 totalPositive 1Neutral 5Negative 0
- Positive단일판매ㆍ공급계약체결(자율공시)2026-04-07
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03
- Neutral주식등의대량보유상황보고서(일반)2026-04-03
- Neutral정기주주총회결과2026-03-23
- Neutral주식매수선택권부여에관한신고2026-03-23